CVM Reorg

[anonymous]

Insiders speak up. Has to be in the next few weeks. Many districts with 6 or fewer reps. Others without managers.Geography’s with two retail reps competing with those who have just 1. All while reporting back to back negative quarterly results.

 

[anonymous]

If you are still hanging on in CVM, then you deserve what you get. You should have left that ship years ago.

 

[anonymous]

I honestly can’t understand how they could be more direct in their communication.
1. Not promotionally sensitive (Katie)
2. Not backfilling specialty positions (Katie)
3. Working toward one specialty rep per territory (Katie)
4. Moving people to other open postitions in 3 waves.
5. National town hall - excited to share the focus/approach for this year which is all top down. HSM/MSL/institution roles were the only roles truly involved in that approach.
6. Back to back loss in revenue.
7. In October she said 3-6 months to finalize plans which puts us at the end of Q1.

So, there will be reductions. They can’t move us all. What we do not know:
1. If maps will be redrawn for territories or if they will only be redrawn for district level.
2. Exact timing. But I personally think it will be mid February. That will allow for the 6 weeks given before severance sets in which would take us all through Q1 and bonuses etc. and allow for a clean start for Q2 with the “right time, right people, right plan” rhetoric.
Thoughts?

 

[anonymous]

Bingo, spot on. Stop bitching and find another job. Pretty simple. Why so us smart people have to help the less fortunate.

 

[anonymous]

Fleet has canceled all orders for CV car replacements why do you think the reason is for that Why do you think there’s that going on that it is because you’re soon to be gone

I honestly can’t understand how they could be more direct in their communication.
1. Not promotionally sensitive (Katie)
2. Not backfilling specialty positions (Katie)
3. Working toward one specialty rep per territory (Katie)
4. Moving people to other open postitions in 3 waves.
5. National town hall - excited to share the focus/approach for this year which is all top down. HSM/MSL/institution roles were the only roles truly involved in that approach.
6. Back to back loss in revenue.
7. In October she said 3-6 months to finalize plans which puts us at the end of Q1.

So, there will be reductions. They can’t move us all. What we do not know:
1. If maps will be redrawn for territories or if they will only be redrawn for district level.
2. Exact timing. But I personally think it will be mid February. That will allow for the 6 weeks given before severance sets in which would take us all through Q1 and bonuses etc. and allow for a clean start for Q2 with the “right time, right people, right plan” rhetoric.
Thoughts?

 

[anonymous]

Bingo, spot on. Stop bitching and find another job. Pretty simple. Why so us smart people have to help the less fortunate.

You don’t sound very smart.

 

[anonymous]

I am laughing at your non selling gravy train riding A$$! No one feels sorry for you except yourself.

 

[anonymous]

Fleet has canceled all orders for CV car replacements why do you think the reason is for that Why do you think there’s that going on that it is because you’re soon to be gone

 

[anonymous]

Fleet has canceled all orders for CV car replacements why do you think the reason is for that Why do you think there’s that going on that it is because you’re soon to be gone

Seriously? All of us gone. You must have the inside scoop, right. Do tell.

 

[anonymous]

Isn't Milvexian launching this year? Isn't BMS and J&J promoting this? That should be fun for the BMS reps. They have to carry a team who can't sell a once a day vs twice a day pill?

 

[anonymous]

Milvexian this year? Uh, no. Clinical trials take years, then peer reviewed, published, then negotiating with FDA. The excitement is current but the launch, if the trials are successful, will take at least a couple more years. IMHO.

 

[anonymous]

Milvexian this year? Uh, no. Clinical trials take years, then peer reviewed, published, then negotiating with FDA. The excitement is current but the launch, if the trials are successful, will take at least a couple more years. IMHO.[/QUOTE
The Afib trial Librexia which is vs Eliquis won’t be completed until May 2027. Generic Eliquis won’t be available until spring of 2028. The other indications for Milvexian may come sooner, I don’t know, but afib would be the money maker if it can beat Eliquis. Possible afib indication wouldn’t happen until sometime in 2028.

 

[anonymous]

Isn't Milvexian launching this year? Isn't BMS and J&J promoting this? That should be fun for the BMS reps. They have to carry a team who can't sell a once a day vs twice a day pill?

 

[anonymous]

Isn't Milvexian launching this year? Isn't BMS and J&J promoting this? That should be fun for the BMS reps. They have to carry a team who can't sell a once a day vs twice a day pill?

the problem is not the sales team, the problem is the schizophrenic ill-conceived messaging and bad management and marketing team. The sales team has been trying, for years, to tell them the key was Q24h dosing. Those folks were pipped out and moved on to greener pastures. Too many stupid reorgs, destroying well cultivated relationships. We quit listening to the customer and the reps on the street who knew more than the dumb asses in the home office.

 

[anonymous]

I have to agree. After launching and sticking with this( foolish I know ) Following the playbook of marketing and Ms T E. Who is an Industrial Engineer and never carried any sales bag for any company(please find a plant to work at you child) she ignored Dr Patel (only the head of Cardiology at Duke) who insisted on a QD dose because compliance = better outcomes in the real world. But no we spoke of CHAds2 and everything but QD.

Thus we got our assxx kicked. What about the patient who is now prescribed Eliquis and misses a dose every other day or worse. How many unnecessary stokes did our marketing strategy cause families. What a shame and a waste. Doesn’t the plant engineer now have a new gig in JNJ. May God help those patients.
Now we have Katie who tells half-truths about the future. So much to say but it doesn’t matter. Lions lead by Lambs. Good luck - I’ll take my severance and retire.

 

[anonymous]

So true

 

[anonymous]

I have to agree. After launching and sticking with this( foolish I know ) Following the playbook of marketing and Ms T E. Who is an Industrial Engineer and never carried any sales bag for any company(please find a plant to work at you child) she ignored Dr Patel (only the head of Cardiology at Duke) who insisted on a QD dose because compliance = better outcomes in the real world. But no we spoke of CHAds2 and everything but QD.

Thus we got our assxx kicked. What about the patient who is now prescribed Eliquis and misses a dose every other day or worse. How many unnecessary stokes did our marketing strategy cause families. What a shame and a waste. Doesn’t the plant engineer now have a new gig in JNJ. May God help those patients.
Now we have Katie who tells half-truths about the future. So much to say but it doesn’t matter. Lions lead by Lambs. Good luck - I’ll take my severance and retire.

The Eliquis patient who misses a dose is taking Xarelto. The drugs have the same half life. The once a day was a marketing tool. Eliquis is preferred because it works just as well with less bleeds, especially GI bleeds. It’s about lowering the risk of adverse outcomes…wonder why the more recent Xarelto indications are twice daily dosing.

 

[anonymous]

I have to agree. After launching and sticking with this( foolish I know ) Following the playbook of marketing and Ms T E. Who is an Industrial Engineer and never carried any sales bag for any company(please find a plant to work at you child) she ignored Dr Patel (only the head of Cardiology at Duke) who insisted on a QD dose because compliance = better outcomes in the real world. But no we spoke of CHAds2 and everything but QD.

Thus we got our assxx kicked. What about the patient who is now prescribed Eliquis and misses a dose every other day or worse. How many unnecessary stokes did our marketing strategy cause families. What a shame and a waste. Doesn’t the plant engineer now have a new gig in JNJ. May God help those patients.
Now we have Katie who tells half-truths about the future. So much to say but it doesn’t matter. Lions lead by Lambs. Good luck - I’ll take my severance and retire.

Absolutely and incredibly well stated. Best of luck to you, cheers mate!

 

[anonymous]

The Eliquis patient who misses a dose is taking Xarelto. The drugs have the same half life. The once a day was a marketing tool. Eliquis is preferred because it works just as well with less bleeds, especially GI bleeds. It’s about lowering the risk of adverse outcomes…wonder why the more recent Xarelto indications are twice daily dosing.

Ummm, maybe because the dose is only 2.5mg. Keep talking out of your ass.

 

[anonymous]

I have to agree. After launching and sticking with this( foolish I know ) Following the playbook of marketing and Ms T E. Who is an Industrial Engineer and never carried any sales bag for any company(please find a plant to work at you child) she ignored Dr Patel (only the head of Cardiology at Duke) who insisted on a QD dose because compliance = better outcomes in the real world. But no we spoke of CHAds2 and everything but QD.

Thus we got our assxx kicked. What about the patient who is now prescribed Eliquis and misses a dose every other day or worse. How many unnecessary stokes did our marketing strategy cause families. What a shame and a waste. Doesn’t the plant engineer now have a new gig in JNJ. May God help those patients.
Now we have Katie who tells half-truths about the future. So much to say but it doesn’t matter. Lions lead by Lambs. Good luck - I’ll take my severance and retire.

All the real world data produced by independent sources- Mayo Clinic, Stanford, Vanderbilt, Brigham & Women’s,etc.- all show less major bleeding and better efficacy with Eliquis. Once the real world data for Afib and VTE began rolling out the market share for Xarelto began to plunge. Where is the real world data showing Xarelto is better than Eliquis at preventing strokes with less bleeds in data sets composed of 100’s of thousands of patients. It doesn’t exist. If it did you would have been running with it. Market share would be flipped. Outcomes matter. Xarelto doesn’t have the data.

Also, the the investigational Factor 11A drugs for Afib are going against Eliquis in the clinicals for a reason.